- Products & Services
- Knowledge Base
PITTSBURGH, PA, June 22, 2020 /24-7PressRelease/ -- Ariel has developed the ADVANCE® precision medicine platform to support the ecosystem of clinicians, patients, pharmaceutical companies and payers working to minimize the impact of chronic disease. Initially targeting pancreatic diseases, we are rapidly expanding the platform's capabilities to address the 60 m patients with chronic digestive disease.
Our clinical decision support tools integrate genetic and clinical data, systems biology, automation and artificial intelligence to determine the biological dysfunction driving a patient's condition and link to evidence-based medicine and treatments tailored for each patient.
Our tools allow clinicians to treat complex patients with expert insights, labs and integrated health systems to gain new insights from genetic and clinical data, and enable drug development companies to segment previously homogenous populations according to the biological drivers of disease in a patient and align those to the specific mechanisms of action of a compound.
The OCMX™ is pleased to announce the listing of Ariel Precision Medicine Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.
The OCMX™ has spent considerable time completing its due diligence on Ariel Precision Medicine Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.
The OCMX™ noted that Ariel Precision Medicine Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
1. Understanding of complex genetics
Ariel has a unique understanding of how combinations of mild to moderate genetic variants act on specific biological functions at the cellular level to cause disease as well as how to repair that damage.
2. Intellectual Property
Ariel has a comprehensive portfolio of patents, trademarks and trade secrets protecting our unique insights.
3. Unique Insights into Complex Disease
Ariel is led by a team of experts including one of the most cited authors in the world on gastrointestinal diseases as well as team members who were instrumental in working with the Cystic Fibrosis Foundation and experts in hereditary cancer genetics.
4. Platform Technology
Ariel's ADVANCE software enables multiple products to be built on one core operating process which allows us to address several markets with our core team.
Jessica Gibson, President & Chief Executive Officer
Ms. Gibson brings sales and marketing expertise and has been a leader in the biotechnology and pharma industries with Gene Wiz, and Shionogi Pharmaceuticals. She consistently won top national awards, was promoted into intensive advanced career development, and led multiple business territories with P&L responsibility.
She is a co-founder of Ariel and served as Chief Commercial Officer until 2016, bringing field knowledge, enthusiasm and service-oriented focus to the company.
Tory Moore CFA, Vice-President & CFO
Prior to becoming involved with Ariel, Mr. Moore worked in the investment management industry in research and portfolio management roles with Greycourt & Co, Fiduciary Asset Management, Triga Capital and Blue Tree Capital.
Seeing an opportunity to help other entrepreneurs with strategy, finance and fundraising, he joined Ariel as CFO in 2015. He earned his MBA at the University of Michigan and holds a B.S. in Economics from Trinity College.
Mark Haupt MD, Chief Medical Officer
Dr. Haupt specializes in advancing new technologies into the medical field. He started his career with a focus on cystic fibrosis, specifically examining epidemiological data to evaluate nutritional outcomes and advising on the development of the software tools to enable that process.
After completing training, Dr. Haupt joined AbbVie, quickly accelerating from their Physician Professional Development Program to a leadership role in the US Medical Affairs organization and earning a President's Award. Dr. Haupt joined Ariel in 2016.
ABOUT THE OCMX™
The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
# # #